OBJECTIVE: To correlate Mx protein (Mx) levels in lysed blood leukocytes with the clinical response to interferon (IFN) beta-1b (IFNbeta-1b) in relapsing-remitting MS (RR-MS) patients for monitoring treatment. BACKGROUND: Intracellular Mx expression is exclusively induced by the type I IFNs (IFN-alpha, -beta, and -omega) or by viruses and is strongly increased under IFN treatment. Quantitative determination of Mx allows objective assessment of biological effects of IFN. METHODS: Mx protein levels were measured in blood leukocyte lysates from IFNbeta-1b-treated RR-MS patients by ELISA and correlated to clinical parameters, including relapse rate and clinical deterioration. RESULTS: In stable IFNbeta-1b-treated MS patients, Mx levels were significantly increased compared to patients with or without immunosuppressive treatment. In IFN-1b-treated MS patients during relapse, Mx levels were significantly lower than during stable phases of the disease. Mean values of Mx (MVMx) over time of treatment in patients with a reduction of relapse rate were significantly higher than in patients without response. CONCLUSION: Mx levels in lysed blood cells may represent a useful surrogate marker for IFNbeta-1b activity corresponding to the clinical response during treatment of MS.
OBJECTIVE: To correlate Mx protein (Mx) levels in lysed blood leukocytes with the clinical response to interferon (IFN) beta-1b (IFNbeta-1b) in relapsing-remitting MS (RR-MS) patients for monitoring treatment. BACKGROUND: Intracellular Mx expression is exclusively induced by the type I IFNs (IFN-alpha, -beta, and -omega) or by viruses and is strongly increased under IFN treatment. Quantitative determination of Mx allows objective assessment of biological effects of IFN. METHODS: Mx protein levels were measured in blood leukocyte lysates from IFNbeta-1b-treated RR-MS patients by ELISA and correlated to clinical parameters, including relapse rate and clinical deterioration. RESULTS: In stable IFNbeta-1b-treated MS patients, Mx levels were significantly increased compared to patients with or without immunosuppressive treatment. In IFN-1b-treated MS patients during relapse, Mx levels were significantly lower than during stable phases of the disease. Mean values of Mx (MVMx) over time of treatment in patients with a reduction of relapse rate were significantly higher than in patients without response. CONCLUSION: Mx levels in lysed blood cells may represent a useful surrogate marker for IFNbeta-1b activity corresponding to the clinical response during treatment of MS.
Authors: C Scagnolari; F Bellomi; S Trombetti; M Casato; M Carlesimo; F Bagnato; V Lavolpe; R Bruno; E Millefiorini; L Antonelli; E Girardi; O Turriziani; G Antonelli Journal: Clin Exp Immunol Date: 2007-02 Impact factor: 4.330
Authors: A Bertolotto; A Sala; S Malucchi; F Marnetto; M Caldano; A Di Sapio; M Capobianco; F Gilli Journal: J Neurol Neurosurg Psychiatry Date: 2004-09 Impact factor: 10.154
Authors: Lisa G M van Baarsen; Saskia Vosslamber; Marianne Tijssen; Josefien M C Baggen; Laura F van der Voort; Joep Killestein; Tineke C T M van der Pouw Kraan; Chris H Polman; Cornelis L Verweij Journal: PLoS One Date: 2008-04-02 Impact factor: 3.240
Authors: Naomi I Maria; Zana Brkic; Matti Waris; Cornelia G van Helden-Meeuwsen; Kim Heezen; Joop P van de Merwe; Paul L van Daele; Virgil A S H Dalm; Hemmo A Drexhage; Marjan A Versnel Journal: Ann Rheum Dis Date: 2013-07-06 Impact factor: 19.103